Market Place
Sourcing Support
Awaiting regulator verdict, Innovent posts latest psoriasis win
29 Oct 2024 //
FIERCE BIOTECH
Innovent Reports Phase 2 Results of Picankibart in Psoriasis
28 Oct 2024 //
PR NEWSWIRE
Innovent Ph 2 Of Picankibart In Ulcerative Colitis Met Endpoint
16 Oct 2024 //
PR NEWSWIRE
Innovent And Ask Pharm Collaborate On Limertinib For Lung Cancer
07 Oct 2024 //
PR NEWSWIRE
Innovent`s NDA For Picankibart Accepted By NMPA
26 Sep 2024 //
PR NEWSWIRE
Innovent links cytokine fusion protein to responses in colorectal cancer
18 Sep 2024 //
FIERCE BIOTECH
Innovent Presents Data In Combination With Bevacizumab For Colorectal Cancer
17 Sep 2024 //
PR NEWSWIRE
Innovent Presents Data In Ovarian, Breast, And Solid Tumors At ESMO 2024
17 Sep 2024 //
PR NEWSWIRE
Innovent`s Mazdutide Shows Superiority Over Dulaglutide In Diabetes Trial
11 Sep 2024 //
PR NEWSWIRE
Innovent Presents IBI363 Phase 1 Data At WCLC 2024
10 Sep 2024 //
PR NEWSWIRE
Innovent Biologics Highlights Lung Cancer Subgroup In Bispecific Study
10 Sep 2024 //
ENDPTS
Innovent Presents Dupert NSCLC Study Results At Lung Cancer Conference
09 Sep 2024 //
PR NEWSWIRE
Dupert Offers Hope As China`s First KRAS G12C Inhibitor For NSCLC
09 Sep 2024 //
EXPRESSPHARMA
Innovent Receives Fast Track Designation from FDA for Advanced Melanoma
03 Sep 2024 //
PR NEWSWIRE
Innovent Annouces Multiple Clinical Study Results of Mazdutide
01 Sep 2024 //
PR NEWSWIRE
Innovent Announces 2024 Interim Results and Business Updates
28 Aug 2024 //
PR NEWSWIRE
Innovent To Present Clinical Data At WCLC And ESMO 2024
28 Aug 2024 //
PR NEWSWIRE
Innovent`s KRAS G12C Inhibitor First Approved In China
22 Aug 2024 //
PR NEWSWIRE
Innovent And SanegeneBio Dose First Participant In IBI3016 Phase 1 Trial
01 Aug 2024 //
PR NEWSWIRE
Innovent`s Mazdutide NDA For Type 2 Diabetes Accepted By NMPA
01 Aug 2024 //
PR NEWSWIRE
Innovent And WeComput Partner For AI-Driven Drug Discovery
25 Jul 2024 //
PR NEWSWIRE
Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug
23 Jul 2024 //
BIOSPACE
Innovent Biologics & IASO Bio enter strategic collaboration in cell therapy
08 Jul 2024 //
PHARMABIZ
Innovent Launches ESG Website To Enhance Sustainability And Responsibility
07 Jul 2024 //
PR NEWSWIRE
Innovent Presents IBI343 Data For Gastric Cancer At ESMO GI Congress
01 Jul 2024 //
PR NEWSWIRE
Innovent Updates Data From Mazdutide GLORY-1 Study And Biomedicine Pipeline
27 Jun 2024 //
PR NEWSWIRE
Innovent links IL-2 fusion protein to responses in small study
15 Jun 2024 //
FIERCE PHARMA
Innovent receives US FDA Fast Track designation for IBI343 as monotherapy
14 Jun 2024 //
PHARMABIZ
Innovent Presents IBI363 Bispecific Data In Advanced NSCLC At ESMO 2024
13 Jun 2024 //
PR NEWSWIRE
Innovent To Present Mazdutide Results At ADA Scientific Sessions
12 Jun 2024 //
PR NEWSWIRE
Innovent Receives FDA Fast Track For IBI343 In Pancreatic Cancer
11 Jun 2024 //
PR NEWSWIRE
Innovent`s IBI389 Bispecific Data In Pancreatic, Gastric Cancers At ASCO
02 Jun 2024 //
PR NEWSWIRE
Innovent`s Taletrectinib ROS1 Inhibitor Data Published, Presented At ASCO
02 Jun 2024 //
PR NEWSWIRE
Innovent`s IBI310 Plus Sintilimab Neoadjuvant Data For Colon Cancer At ASCO
02 Jun 2024 //
PR NEWSWIRE
Innovent`s IBI363 PD-1/IL-2? Bispecific Shows Phase 1 Solid Tumor Data
01 Jun 2024 //
PR NEWSWIRE
Innovent`s IBI343 Anti-CLDN18.2 ADC Data In Pancreatic, Biliary Cancers
01 Jun 2024 //
PR NEWSWIRE
Innovent`s Taletrectinib ROS1 Inhibitor Pivotal Data Published, At ASCO
01 Jun 2024 //
PR NEWSWIRE
Innovent’s ph3 study of picankibart to treat moderate to severe plaque psoriasis
29 May 2024 //
PHARMABIZ
Innovent looks to Chinese regulators after ph. 3 psoriasis win
28 May 2024 //
FIERCE BIOTECH
Innovent Picankibart Phase 3 Success: Psoriasis Nmpa Nda Filing Planned
27 May 2024 //
PR NEWSWIRE
Innovent`s IBI311 NDA Accepted In China For Thyroid Eye Disease
20 May 2024 //
PR NEWSWIRE
Innovent Announces IBI363, IBI343 Data At ESMO Meetings
19 May 2024 //
PR NEWSWIRE
Lilly`s next-gen obesity drug brings Innovent ph. 3 diabetes win
09 May 2024 //
FIERCE BIOTECH
Innovent: Mazdutide Phase 3 Trial in Chinese Type 2 Diabetes Patients
08 May 2024 //
PR NEWSWIRE
Innovent gets breakthrough designation for IBI343 in gastric cancer.
06 May 2024 //
PR NEWSWIRE
Innovent Appoints Dr. Samuel Zhang as Global CBO
29 Apr 2024 //
PR NEWSWIRE
Innovent Presents Multiple Molecules at ASCO 2024
24 Apr 2024 //
PR NEWSWIRE
Innovent Appoints Dr. Nageatte Ibrahim As Oncology CMO
15 Apr 2024 //
PR NEWSWIRE
Innovent to Present Preclinical Data of Multiple Novel Molecules at the AACR
07 Apr 2024 //
PR NEWSWIRE
Innovent Announces 2023 Annual Results and Business Updates
20 Mar 2024 //
PR NEWSWIRE
Innovent Announces Primary Endpoint Met in Ph 2 of IBI302 in Treating nAMD
18 Mar 2024 //
PR NEWSWIRE
Innovent`s Tepezza rival closer to China nod after phase 3 win
20 Feb 2024 //
FIERCE BIOTECH
Innovent Announces Primary Endpoint Met in Phase 3 Trial (RESTORE-1) of IBI311
19 Feb 2024 //
PR NEWSWIRE
Innovent`s First NDA of Mazdutide has been Accepted by the NMPA of China
07 Feb 2024 //
PR NEWSWIRE
Innovent Announces Retirement of CFO and Appointment of New CFO
05 Feb 2024 //
PR NEWSWIRE
Innovent`s Phase III obesity treatment trial meets all endpoints
10 Jan 2024 //
CLINICAL TRIALS ARENA
Next-gen Lilly obesity drug secures first phase 3 win for Innovent
09 Jan 2024 //
FIERCE BIOTECH
Innovent Announces the First Phase 3 Trial of Mazdutide in Chinese Adults
08 Jan 2024 //
PR NEWSWIRE
Innovent Dosed First Participant in Phase 3 Clinical Study of Mazdutide
01 Jan 2024 //
PR NEWSWIRE
Innovent and Xuanzhu Enter into Clinical Trial Collaboration
27 Dec 2023 //
PR NEWSWIRE
